Drug discovery to reverse clarithromycin resistance in multidrug-resistant mycobacterium abscessus
Mycobacterium abscessus is an emerging life-threatening non-tuberculous mycobacterium with extensive drug-resistance mechanisms. M. abscessus infections have been causing substantial economic burden, due to the lengthy treatment lasting up to 24 months with multi-drug regimens. Despite this extensiv...
Saved in:
Main Author: | Dam, Linh Chi |
---|---|
Other Authors: | Julien Lescar |
Format: | Final Year Project |
Language: | English |
Published: |
2019
|
Subjects: | |
Online Access: | http://hdl.handle.net/10356/78040 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Rifaximin potentiates clarithromycin against Mycobacterium abscessus in vitro and in zebrafish
by: Goh, Boon Chong, et al.
Published: (2024) -
Vancomycin and clarithromycin show synergy against Mycobacterium abscessus in vitro
by: Mukherjee, D, et al.
Published: (2020) -
Antibiograms and molecular characterization of drug resistance of Mycobacterium abscessus complex from patients with multidrug-resistant pulmonary tuberculosis (MDR-TB) infection
by: Bongulto, Kenneth A.
Published: (2019) -
Rifabutin suppresses inducible clarithromycin resistance in mycobacterium abscessus by blocking induction of whiB7 and erm41
by: Aziz, D.B., et al.
Published: (2021) -
Evaluating the attractiveness of the terminal oxidases as drug targets in mycobacterium abscessus
by: Sorayah, Ria
Published: (2022)